Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Sofosbuvir/Ledipasvir ± Ribavirin in Japanese Participants With Chronic Genotype 1 HCV Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Body weight ≥ 40 kg~* HCV RNA ≥ 10\^5 IU/mL at screening~Exclusion Criteria:~* Current or prior history of any clinically-significant illness (other than HCV)~* Pregnant or nursing female or male with pregnant female partner~* Chronic liver disease of a non-HCV etiology~* Infection with hepatitis B virus (HBV) or human immunodeficiency virus (HIV)

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- LDV/SOF (treatment naive) (Type: EXPERIMENTAL): Treatment-naive participants will receive LDV/SOF for 12 weeks.
- LDV/SOF+RBV (treatment naive) (Type: EXPERIMENTAL): Treatment-naive participants will receive LDV/SOF plus RBV for 12 weeks.
- LDV/SOF (treatment experienced) (Type: EXPERIMENTAL): Treatment-experienced participants will receive LDV/SOF for 12 weeks.
- LDV/SOF+RBV (treatment experienced) (Type: EXPERIMENTAL): Treatment-experienced participants will receive LDV/SOF plus RBV for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).